RFK Jr: Vaccine Adviser & Autism Link Debate
- A revamped vaccine advisory panel,handpicked by Health and Human Services Secretary Robert F.
- This marks the first ACIP meeting as Kennedy dismissed all 17 members and appointed eight new panelists, some of whom have publicly criticized vaccines.
- ACIP plays a crucial role in recommending vaccines for childhood and adult schedules based on safety data.
Robert F. Kennedy Jr.’s influence on vaccine policy takes center stage. A new advisory panel, handpicked by the HHS Secretary, will vote on the safety of thimerosal, a key primary_keyword, and revisit measles vaccine use. The meeting marks a meaningful shift, with Kennedy replacing existing members. The debate centers on a controversial link between thimerosal and autism, a link that’s been widely debunked by scientific studies. The committee will reconsider vaccine recommendations, opening the door for potential changes to vaccine schedules. The upcoming discussion will focus on influenza vaccines, and a panel’s previous discussion regarding the MMRV vaccines remains unclear. The role of ACIP in vaccine recommendations and how insurers recognize their recommendations is essential in discussing these topics. Stay informed with News Directory 3 for comprehensive analysis of the meeting. Discover what’s next in vaccine safety.
Vaccine Panel to Revisit Thimerosal Safety,Measles Vaccine Use
Updated june 18,2025
A revamped vaccine advisory panel,handpicked by Health and Human Services Secretary Robert F. Kennedy Jr., is scheduled to vote on the safety of thimerosal, a vaccine ingredient previously linked to autism, during its two-day meeting next week. The Advisory Committee on immunization Practices (ACIP) will also revisit the use of the measles vaccine in children younger than 5 years old.
This marks the first ACIP meeting as Kennedy dismissed all 17 members and appointed eight new panelists, some of whom have publicly criticized vaccines. The draft agenda includes revisiting topics considered settled by scientists and public health experts.
ACIP plays a crucial role in recommending vaccines for childhood and adult schedules based on safety data. insurers typically cover vaccines endorsed by ACIP.
The committee will specifically vote on recommendations concerning influenza vaccines containing thimerosal. kennedy has long advocated for banning thimerosal,a preservative used for decades in various biological and drug products,including vaccines. In his 2014 book,Kennedy claimed thimerosal was “toxic to brain tissue” and potentially caused autism.
Thimerosal, a mercury-containing compound, prevents harmful bacteria in multidose vaccine vials. The Centers for Disease Control and Prevention (CDC) notes that manufacturers have largely shifted to single-use vials with little to no thimerosal.
While thimerosal was removed from most pediatric vaccines by 2001 due to autism concerns, numerous studies have since debunked this link. The CDC states that “a robust body of peer-reviewed scientific studies conducted in the U.S.and other countries support the safety of thimerosal-containing vaccines.” The agency also points out that autism rates continued to rise even after thimerosal’s removal, contradicting the theory that it causes autism.
Currently, thimerosal is used in three adult flu vaccines sold by Sanofi and CSL Seqirus, according to the Food and Drug Governance.
The panel’s discussion regarding the measles, mumps, rubella and varicella vaccines (MMRV) remains unclear. The CDC recommends two doses of the MMR vaccine for children, with the first dose at 12-15 months and the second at 4-6 years.The CDC suggests the MMR vaccine over MMRV for the first dose, though both have been on the schedule for decades.
The current agenda is more focused than previous schedules. Votes on recommendations for COVID-19 vaccines, as well as HPV and meningococcal vaccines, have been removed.
Last month,Kennedy altered the CDC’s COVID-19 vaccine recommendation without a panel vote.
What’s next
The upcoming ACIP meeting will likely spark debate as the panel considers revisiting established vaccine safety and scheduling recommendations, particularly concerning thimerosal and the measles vaccine. The outcomes of these votes could considerably impact vaccine policy and public health initiatives.